<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(AMENDMENT NO. 1)
Under the Securities Exchange Act of 1934
INTEGRATED ORTHOPAEDICS, INC.
-----------------------------------------------------------------------
(Name of issuer)
COMMON STOCK, $.001 PAR VALUE
-----------------------------------------------------------------------
(Title of class of securities)
45812K108
-----------------------------------------------------------------------
(CUSIP number)
ANTHONY MARINATOS
ONE INDEPENDENT DRIVE, SUITE 3120
JACKSONVILLE, FLORIDA 32202
(904) 355-3519
-----------------------------------------------------------------------
(Name, address and telephone number of person
authorized to receive notices and communications)
September 15, 2000
-----------------------------------------------------------------------
(Date of event which requires filing of this statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box. / /
(Continued on following pages)
(Page 1 of 9)
<PAGE>
--------------------
CUSIP NO. 45812K108 SCHEDULE 13D
--------------------
-----------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
CHARTWELL CAPITAL INVESTORS, L.P.
-----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(See Instructions) (b) / /
-----------------------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
WC
-----------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) or 2(e) / /
-----------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
-----------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 0
SHARES
BENEFICIALLY ---------------------------------------------
OWNED BY 8 SHARED VOTING POWER 2,373,863
EACH
REPORTING ---------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER 0
---------------------------------------------
10 SHARED DISPOSITIVE POWER 2,373,863
-----------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,373,863
-----------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) / /
-----------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.02% (1)
-----------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
PN
-----------------------------------------------------------------------------
(1) Based on a total of 29,592,741 shares of Common Stock outstanding as stated
in the Issuer's Quarterly Report on Form 10-QSB filed with the Securities and
Exchange Commission on August 21, 2000.
(Page 2 of 9)
<PAGE>
--------------------
CUSIP NO. 45812K108 SCHEDULE 13D
--------------------
-----------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
CHARTWELL CAPITAL PARTNERS, L.P.
-----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(See Instructions) (b) / /
-----------------------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
AF
-----------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) or 2(e) / /
-----------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
-----------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 0
SHARES
BENEFICIALLY ---------------------------------------------
OWNED BY 8 SHARED VOTING POWER 2,373,863
EACH
REPORTING ---------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER 0
---------------------------------------------
10 SHARED DISPOSITIVE POWER 2,373,863
-----------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,373,863
-----------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) / /
-----------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.02% (1)
-----------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
PN
-----------------------------------------------------------------------------
(1) Based on a total of 29,592,741 shares of Common Stock outstanding as stated
in the Issuer's Quarterly Report on Form 10-QSB filed with the Securities and
Exchange Commission on August 21, 2000.
(Page 3 of 9)
<PAGE>
--------------------
CUSIP NO. 45812K108 SCHEDULE 13D
--------------------
-----------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
CHARTWELL PARTNERS, L.P.
-----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(See Instructions) (b) / /
-----------------------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
AF
-----------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) or 2(e) / /
-----------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
-----------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 0
SHARES
BENEFICIALLY ---------------------------------------------
OWNED BY 8 SHARED VOTING POWER 2,373,863
EACH
REPORTING ---------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER 0
---------------------------------------------
10 SHARED DISPOSITIVE POWER 2,373,863
-----------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,373,863
-----------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) / /
-----------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.02% (1)
-----------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
PN
-----------------------------------------------------------------------------
(1) Based on a total of 29,592,741 shares of Common Stock outstanding as stated
in the Issuer's Quarterly Report on Form 10-QSB filed with the Securities and
Exchange Commission on August 21, 2000.
(Page 4 of 9)
<PAGE>
--------------------
CUSIP NO. 45812K108 SCHEDULE 13D
--------------------
-----------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
CHARTWELL, INC.
-----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(See Instructions) (b) / /
-----------------------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
AF
-----------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) or 2(e) / /
-----------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
FLORIDA
-----------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 0
SHARES
BENEFICIALLY ---------------------------------------------
OWNED BY 8 SHARED VOTING POWER 2,373,863
EACH
REPORTING ---------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER 0
---------------------------------------------
10 SHARED DISPOSITIVE POWER 2,373,863
-----------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,373,863
-----------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) / /
-----------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.02% (1)
-----------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
CO
-----------------------------------------------------------------------------
(1) Based on a total of 29,592,741 shares of Common Stock outstanding as stated
in the Issuer's Quarterly Report on Form 10-QSB filed with the Securities and
Exchange Commission on August 21, 2000.
(Page 5 of 9)
<PAGE>
--------------------
CUSIP NO. 45812K108 SCHEDULE 13D
--------------------
Pursuant to Rule 13d-2(a) of Regulation 13D-G of the General Rules and
Regulations under the Securities Exchange Act of 1934, as amended (the "Act"),
the undersigned hereby amend their Schedule 13D Statement dated May 21, 1996
(this "Schedule 13D"), relating to the Common Stock, $.001 par value, of
Integrated Orthopaedics, Inc., formerly known as DRCA Medical Corporation, a
Texas corporation.
ITEM 1. SECURITY AND ISSUER.
Item 1 of this Schedule 13D is hereby amended in its entirety to read
as follows:
"The class of equity securities to which this statement relates is the
common stock, $0.001 par value per share (the "Common Stock"), of Integrated
Orthopaedics, Inc., formerly known as DRCA Medical Corporation, a Texas
corporation (the "Issuer"), which has its principal executive offices at 1800
West Loop South, Suite 1030, Houston, Texas 77027."
ITEM 4. PURPOSE OF TRANSACTION.
Item 4 of this Schedule 13D is hereby amended by adding the following
paragraphs:
"On August 2, 2000, CCI converted (the "Conversion") 25,226 shares of
the Issuer's Series A Preferred Stock into 2,373,863 shares of Common Stock.
"On September 15, 2000, the Issuer and PowerBrief, Inc. entered into an
Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which
PowerBrief, Inc. is to merge with and into the Issuer (the "Merger") on the
terms and conditions set forth in the Merger Agreement.
"As an inducement to cause PowerBrief, Inc. to enter into the Merger
Agreement, CCI and certain other shareholders of the Issuer have concurrently
therewith entered into a voting agreement with PowerBrief, Inc. in the form
filed herewith as Exhibit 99.H (the "Voting Agreement"), pursuant to which,
among other things, CCI and such shareholders have agreed (i) to vote all shares
of Common Stock owned by them in favor of the Merger; (ii) to vote all shares of
Common Stock owned by them against all other proposals submitted to shareholders
of the Issuer that, directly or indirectly, would reasonably be expected to
prevent or materially delay the consummation of the Merger; and (iii) to grant
irrevocable proxies and powers of attorney to vote the shares of Common Stock
owned by them."
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
The first paragraph of Item 5 of this Schedule 13D is hereby amended to
read as follows:
"CCI beneficially and directly owns 2,373,863 shares of the outstanding
Common Stock, constituting approximately 8.02% of the outstanding Common Stock,
based on a total of 29,592,741 shares of Common Stock outstanding as of August
14, 2000 (as stated in the Issuer's Quarterly Report on Form 10-QSB filed with
the Securities and Exchange Commission on August 21, 2000). CCP, CP, and CI may
be deemed to beneficially own such shares of Common Stock directly owned by CCI
and to share voting and dispositive power with CCI with
(Page 6 of 9)
<PAGE>
--------------------
CUSIP NO. 45812K108 SCHEDULE 13D
--------------------
respect to such shares. For information concerning the acquisition of these
shares pursuant to the Conversion, and concerning the Voting Agreement among
Powerbrief, Inc. and CCI and certain other shareholders of the Issuer, see
Item 4 hereof. None of the other persons listed in Item 2 hereof beneficially
owns any shares of Common Stock."
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
Item 6 of this Schedule 13D is hereby amended by adding the following:
Incorporated by reference herein as Exhibit 99.G is a letter pursuant
to which CCI effected the Conversion.
Incorporated by reference herein as Exhibit 99.H is the Voting
Agreement. For information concerning the Voting Agreement, see Item 4 hereof.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
Item 7 of this Schedule 13D is hereby amended by adding the following:
Exhibit No.
99.E Agreement and Plan of Merger, dated September 15, 2000, by and
between PowerBrief, Inc. and Integrated Orthopaedics, Inc.
(incorporated herein by reference to Exhibit 99.2 of the Current Report
on Form 8-K dated September 21, 2000 filed by the Issuer).
99.F Letter dated July 26, 2000 to Robert L. Stein from FW Integrated
Orthopaedics Investors, L.P. and FW Integrated Orthopaedics Investors
II, L.P., with respect to the Conversion (incorporated by reference to
Exhibit 99.6 to Amendment No. 5 (the "FW Schedule 13D Amendment") dated
August 4, 2000 to the Schedule 13D filed with respect to Common Stock
owned by FW Integrated Orthopaedics Investors, L.P., Group 31, Inc., FW
Integrated Orthopaedics Investors II, L.P., and Group Special
Investments, Inc.).
99.G Letter dated August 1, 2000 from CCI to the Issuer regarding the
Conversion (incorporated by reference to Exhibit 99.7 of the FW
Schedule 13D Amendment).
99.H Voting Agreement dated September 15, 2000 among PowerBrief, Inc.,
CCI and the other signatories thereto.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certify that the information set forth in this statement with
respect to it is true, complete and correct.
(Page 7 of 9)
<PAGE>
--------------------
CUSIP NO. 45812K108 SCHEDULE 13D
--------------------
Date: October 5, 2000 CHARTWELL CAPITAL INVESTORS, L.P.
By: Chartwell Capital Partners, L.P.,
its General Partner
By: Chartwell Partners, L.P.,
its General Partner
By: Chartwell, Inc.,
its General Partner
By: /s/ Mindy Lanigan
-----------------------
Mindy Lanigan
Vice President and
Chief Financial Officer
(Page 8 of 9)
<PAGE>
--------------------
CUSIP NO. 45812K108 SCHEDULE 13D
--------------------
EXHIBIT LIST
Exhibit 99.E Agreement and Plan of Merger, dated September 15, 2000, by and
between PowerBrief, Inc. and Integrated Orthopaedics, Inc. (incorporated herein
by reference to Exhibit 99.2 of the Current Report on Form 8-K dated
September 21, 2000 filed by the Issuer).
Exhibit 99.F Letter dated July 26, 2000 to Robert L. Stein from FW Integrated
Orthopaedics Investors, L.P. and FW Integrated Orthopaedics Investors II, L.P.,
with respect to the Conversion (incorporated by reference to Exhibit 99.6 to
Amendment No. 5 (the "FW Schedule 13D Amendment") dated August 4, 2000 to the
Schedule 13D filed with respect to Common Stock owned by FW Integrated
Orthopaedics Investors, L.P., Group 31, Inc., FW Integrated Orthopaedics
Investors II, L.P., and Group Special Investments, Inc.).
Exhibit 99.G Letter dated August 1, 2000 from CCI to the Issuer regarding the
Conversion (incorporated by reference to Exhibit 99.7 of the FW Schedule 13D
Amendment).
Exhibit 99.H Voting Agreement dated September 15, 2000 among PowerBrief, Inc.,
CCI and the other signatories thereto.
(Page 9 of 9)
<PAGE>
